Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HNSA | Stockholm | SEK | Real-time | |
HNSAs | BATS Europe | SEK | Delayed | |
24H | Frankfurt | EUR | Delayed |
Hansa Biopharma AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2024. For the third quarter, the company reported sales was SEK 48.66 million compared to SEK 22.84 million a year ago. Net loss was SEK 103.8 million compared to SEK 250.66 million a year ago. Basic loss per share from continuing operations was SEK 1.53 compared to SEK 4.78 a year ago. Diluted loss per share from continuing operations was SEK 1.53 compared to SEK 4.78 a year ago. For the nine months, sales was SEK 138.98 million compared to SEK 83.68 million a year ago. Net loss was SEK 530.32 million compared to SEK 707.26 million a year ago. Basic loss per share from continuing operations was SEK 8.67 compared to SEK 13.49 a year ago. Diluted loss per share from continuing operations was SEK 8.67 compared to SEK 13.49 a year ago.
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Revenue | 48.66 | 34.33 | 55.98 | 50.41 |
Gross Profit | 37.28 | -6.19 | 37.82 | 32.28 |
Operating Income | -116.93 | -187.38 | -159.39 | -175.54 |
Net Income | -103.8 | -207.94 | -218.58 | -124.46 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Total Assets | 940.68 | 1029.38 | 830.55 | 1018.04 |
Total Liabilities | 1260.63 | 1248.17 | 1204.76 | 1185.92 |
Total Equity | -319.96 | -218.79 | -374.21 | -167.88 |
Period Ending: | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -148.8 | -189.14 | -189.14 | -172.94 |
Cash From Investing Activities | -0.116 | 0.405 | ||
Cash From Financing Activities | -1.89 | 352.43 | -1.86 | -2.2 |
Net Change in Cash | -151.46 | 163.53 | -190.6 | -176.12 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review